Navigation Links
AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
Date:11/3/2008

eated with various chemotherapies.

The study showed that AEZS-108 was well tolerated by patients with gynaecological tumors. Furthermore, AEZS-108 is the first drug in a clinical study that targets the cytotoxic activity of doxorubicin specifically to LHRH-receptor expressing tumors. Finally, signs of anti-tumor activity were observed in 7 out of 13 patients treated with 160 or 267 mg/m2 of AEZS-108, including three patients with complete or partial response.

About AEZS-108

AEZS-108 represents a new targeting concept in oncology using a cytotoxic peptide conjugate which is a hybrid molecule composed of a synthetic peptide carrier and a well-known cytotoxic agent, doxorubicin. The design of this product allows for the specific binding and selective uptake of the cytotoxic conjugate by LHRH-receptor-positive tumors. The binding of AEZS-108 to cancerous cells that express these receptors, results in its accumulation in the malignant tissue. This binding is followed by internalization and retention of the cytotoxic drug, doxorubicin, in the cells. Therefore, since they target specific cells, cytotoxic conjugates are postulated to be less toxic, have less side-effects and are more effective in vivo than the respective non-conjugated/non-linked cytotoxic agents in inhibiting tumor growth.

About endometrial and Ovarian Cancer

Cancer of the endometrium is the most common gynaecologic malignancy and accounts for 6% of all cancers in women. The majority of the cases occur in postmenopausal women, with the largest number of women developing their cancers during the sixth decade. Approximately 38,000 new cases and 9,000 deaths from this disease are estimated annually in Europe (Source: Annals of Oncology 15:1149-1150, 2004).

Ovarian cancer is one of the most common gynaecologic malignancies and the fifth most frequent cause of cancer death in women, with most of the cases occurring in women between 50 and 75 years of age. Overall, ovari
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 Whitehouse Laboratories ... by the Parenteral Drug Association (PDA) to ... 2014) on container closure integrity testing. This lecture/laboratory course ... methods and philosophies detailed in the recently proposed revision ... The course will span container closure integrity testing ...
(Date:9/30/2014)... MA and Pittsburgh PA (PRWEB) September 30, 2014 ... Clinical Research Nurses ( IACRN), a non-profit ... Alliance for Clinical Research Excellence and Safety ... the signing of a strategic alliance agreement, setting ... IACRN’s vision is to enhance clinical research quality ...
(Date:9/29/2014)... forefront of diagnostics today, with imaging techniques like ... and NMR (nuclear magnetic resonance) increasing steeply over ... image resolution and quality still limit these techniques ... solution is hyperpolarization, which involves injecting the patient ... following the distribution and fate of specific molecules ...
(Date:9/29/2014)... Sept. 29, 2014  Ten of the most ... cartilage repair, regeneration, allograft reconstruction and research and ... world gathered to discuss the future of cartilage ... Regenerative Medicine symposium, Cartilage Regeneration: State of ... Orthopedic Biosurgery, Minced Juvenile Allograft, and State of ...
Breaking Biology Technology:Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 3Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 4IACRN and ACRES to Support Clinical Research Nurses 2IACRN and ACRES to Support Clinical Research Nurses 3A safer approach for diagnostic medical imaging 2A safer approach for diagnostic medical imaging 3World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3
... (Nasdaq: AMLN ) issued the following statement ... Eastbourne Capital Management, L.L.C., made public earlier today:"After significant ... unable to achieve a settlement with Eastbourne and Carl ... shareholders. Of course, we continue to remain open to ...
... ATLANTA, May 20 Germany will present itself ... locations at this year,s BIO,International Convention. Under the ... will provide invaluable insight into the,latest research results ... The,German research landscape and the regulatory framework conditions ...
... N.C., May 20 Asymchem Laboratories, Inc., a leading ... Products to the pharmaceutical industry, with sites in ... the recent addition of Dr. Chris Huber as ... the table over 15 years experience in the ...
Cached Biology Technology:Amylin Responds to Eastbourne Letter 2Amylin Responds to Eastbourne Letter 3Amylin Responds to Eastbourne Letter 4BIO International Convention 2009: Research Location Germany Presents Potential in Regenerative Medicine 2Dr. Chris Huber Joins Asymchem Laboratories Inc. as Director of Chemical Development 2
(Date:9/30/2014)... The New England Journal of Medicine reports ... the drug crizotinib against the subset of lung cancer ... multi-center study of 50 patients with advanced non-small cell ... response rate was 72 percent, with 3 complete responses ... time it takes for the disease to resume its ...
(Date:9/30/2014)... (LMU) in Munich report that a new class ... to chemotherapeutic drugs. They have also pinpointed the ... for anti-tumor agents. , Researchers led by ... of the Technische Universitt Mnchen have identified a ... weapon in the fight against malignant tumors. The ...
(Date:9/30/2014)... of perilous threats in today,s ocean. From overfishing ... fragile coral ecosystems are disappearing at unprecedented rates ... of corals surrounding the island of Moorea in ... tropical environment: coral guard-crabs. New research from the ... scientist Seabird McKeon and the museum,s predoctoral fellow ...
Breaking Biology News(10 mins):NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2Cancer therapy: Driving cancer cells to suicide 2Smithsonian scientists discover coral's best defender against an army of sea stars 2
... recent study led by scientists from the National University of ... Spinal Muscular Atrophy (SMA), a devastating disease that is the ... young adults. As there is currently no known cure for ... fight against SMA. SMA is caused by deficiencies ...
... , Dec. 18, 2013 Tissue engineering ... a regenerative or reparative medicine with potential to ... engineering, which involve leveraging technologies from biomaterials, molecular ... the restructure and/or repair of human organs through ...
... have shown for the first time that the specialised role ... cilia tiny hair-like structures protruding from a cell. Stem ... body through the process of differentiation. The discovery ... therapies for a range of medical treatments where scientists aim ...
Cached Biology News:Study led by NUS scientists provides new insights into cause of human neurodegenerative disease 2Study led by NUS scientists provides new insights into cause of human neurodegenerative disease 3State-of-the-Art Tissue Engineering and Organ Regeneration Technologies Yield Healthcare Market Disruption 2State-of-the-Art Tissue Engineering and Organ Regeneration Technologies Yield Healthcare Market Disruption 3State-of-the-Art Tissue Engineering and Organ Regeneration Technologies Yield Healthcare Market Disruption 4
Features , Designed to assist users in applying domed caps to tube strips and plates , Minimises the pressure required to seal the caps effectively , Enables multiple tubes to be sealed simultaneousl...
Lysozyme C (W-20)...
... and BR4i refrigerated multifunction centrifuges are equally capable ... a low sound level with a large range ... AUTO-LOCK rotor exchange system without tools ensures that ... seconds. Instant rotor exchange (5 sec.) ...
... X-Gal (5-bromo-4-chloro-3-indoyl-beta-D-galactopyranoside) is a ... identify recombinant plasmids. In ... and IPTG, lac ... blue, whereas recombinant colonies ...
Biology Products: